Preliminary second-quarter revenue and financing update
Autolus Therapeutics reported preliminary second-quarter 2026 net product revenue and announced a credit facility of up to $250 million with Perceptive Advisors.
The company raised its fiscal 2026 sales guidance to $140 million-$150 million.
Autolus said preliminary second-quarter 2026 AUCATZYL net product revenue was about $45 million.
AUTL•
